新医学
新醫學
신의학
New Medicine
2015年
11期
732-736
,共5页
张增强%叶永康%黄亚强%吴永定%李牧%何慧婵
張增彊%葉永康%黃亞彊%吳永定%李牧%何慧嬋
장증강%협영강%황아강%오영정%리목%하혜선
前列腺癌%肌球蛋白轻链%蛋白质组学%临床预后
前列腺癌%肌毬蛋白輕鏈%蛋白質組學%臨床預後
전렬선암%기구단백경련%단백질조학%림상예후
Prostate cancer%Myosin light chain%Proteomics%Clinical prognosis
目的:研究人肌球蛋白轻链9(MYL9)在前列腺癌中的表达水平及其对临床生化复发的预测价值。方法利用蛋白质组学技术检测前列腺癌及癌旁良性前列腺组织 MYL9的表达水平,再通过蛋白免疫印迹法验证蛋白质组学结果,最后使用 Taylor 的数据对 MYL9进行生物信息学分析,分析不同年龄、血清 PSA 水平、Gleason 评分、病理分期、转移与否及生存与否的前列腺癌患者间MYL9水平的差异。结果蛋白质组学结果显示,MYL9在前列腺癌组织中的表达水平比癌旁良性前列腺组织下调5.67倍(P <0.01);蛋白免疫印迹法结果也显示,前列腺癌组织中 MYL9表达水平比癌旁良性前列腺组织明显下调(0.23±0.08 vs.0.73±0.06,P <0.001);前列腺癌患者中,年龄<66岁、Gleason 评分<8分、病理分期<T3A、肿瘤无转移、存活者的 MYL9表达水平明显高于年龄≥66岁、Gleason 评分≥8分、病理分期≥T3A、肿瘤发生转移、死亡者(P 均<0.001),血清 PSA水平是否<4μg/L 对 MYL9表达无影响(P >0.05)。MYL9低表达组前列腺癌患者的无生化复发生存率明显低于 MLY9高表达组(χ2=11.575,P <0.001)。结论MYL9在前列腺癌中比癌旁前列腺组织表达下调,且 MYL9表达水平较低者的临床预后较差。
目的:研究人肌毬蛋白輕鏈9(MYL9)在前列腺癌中的錶達水平及其對臨床生化複髮的預測價值。方法利用蛋白質組學技術檢測前列腺癌及癌徬良性前列腺組織 MYL9的錶達水平,再通過蛋白免疫印跡法驗證蛋白質組學結果,最後使用 Taylor 的數據對 MYL9進行生物信息學分析,分析不同年齡、血清 PSA 水平、Gleason 評分、病理分期、轉移與否及生存與否的前列腺癌患者間MYL9水平的差異。結果蛋白質組學結果顯示,MYL9在前列腺癌組織中的錶達水平比癌徬良性前列腺組織下調5.67倍(P <0.01);蛋白免疫印跡法結果也顯示,前列腺癌組織中 MYL9錶達水平比癌徬良性前列腺組織明顯下調(0.23±0.08 vs.0.73±0.06,P <0.001);前列腺癌患者中,年齡<66歲、Gleason 評分<8分、病理分期<T3A、腫瘤無轉移、存活者的 MYL9錶達水平明顯高于年齡≥66歲、Gleason 評分≥8分、病理分期≥T3A、腫瘤髮生轉移、死亡者(P 均<0.001),血清 PSA水平是否<4μg/L 對 MYL9錶達無影響(P >0.05)。MYL9低錶達組前列腺癌患者的無生化複髮生存率明顯低于 MLY9高錶達組(χ2=11.575,P <0.001)。結論MYL9在前列腺癌中比癌徬前列腺組織錶達下調,且 MYL9錶達水平較低者的臨床預後較差。
목적:연구인기구단백경련9(MYL9)재전렬선암중적표체수평급기대림상생화복발적예측개치。방법이용단백질조학기술검측전렬선암급암방량성전렬선조직 MYL9적표체수평,재통과단백면역인적법험증단백질조학결과,최후사용 Taylor 적수거대 MYL9진행생물신식학분석,분석불동년령、혈청 PSA 수평、Gleason 평분、병리분기、전이여부급생존여부적전렬선암환자간MYL9수평적차이。결과단백질조학결과현시,MYL9재전렬선암조직중적표체수평비암방량성전렬선조직하조5.67배(P <0.01);단백면역인적법결과야현시,전렬선암조직중 MYL9표체수평비암방량성전렬선조직명현하조(0.23±0.08 vs.0.73±0.06,P <0.001);전렬선암환자중,년령<66세、Gleason 평분<8분、병리분기<T3A、종류무전이、존활자적 MYL9표체수평명현고우년령≥66세、Gleason 평분≥8분、병리분기≥T3A、종류발생전이、사망자(P 균<0.001),혈청 PSA수평시부<4μg/L 대 MYL9표체무영향(P >0.05)。MYL9저표체조전렬선암환자적무생화복발생존솔명현저우 MLY9고표체조(χ2=11.575,P <0.001)。결론MYL9재전렬선암중비암방전렬선조직표체하조,차 MYL9표체수평교저자적림상예후교차。
Objective To investigate the expression level and predictive value of myosin light chain 9 (MYL9)in the biochemical recurrence of prostate cancer.Methods The expression levels of MYL9 in the prostate cancer and adjacent benign prostate tissues were assessed by proteomics technique and the results were further validated by western blot.Eventually,the bioinformatics analysis of MYL9 was performed using Taylor data to analyze the difference in the expression of MYL9 among prostate cancer patients with different ages,ser-um PSA levels,Gleason scores,pathological stages,whether metastasis or not and whether survived or not. Results Proteomics results revealed that the expression level of MYL9 in the prostate cancer tissue was down-regulated by 5.67 times compared with that in the adjacent benign prostate tissue (P <0.01);Western blot a-nalysis indicated that the expression level of MYL9 in the prostate cancer tissue was 0.23 ±0.08,significantly lower compared with 0.73 ±0.06 in the adjacent benign prostate tissue (P <0.001);The expression of MYL9 in prostate cancer patients aged <66 years,with Gleason score <8,pathological staging <T3A,no tumor me-tastasis and the survived was significantly higher than that in their counterparts aged ≥66 years,Gleason score≥8,with pathological staging ≥T3A,tumor metastasis and the dead (all P <0.001).Whether serum PSA level <4 μg/L exerted no effect on the expression of MYL9 (P >0.05).The biochemical recurrence-free sur-vival rate in prostate cancer patients with low expression of MYL9 was significantly lower compared with that in their counterparts highly expressing MLY9 (χ2 =11.575,P <0.001).Conclusions MYL9 expression in the prostate cancer tissue was down-regulated compared with that in adjacent normal prostate tissue.Patients with lower expression level of MYL9 yielded worse clinical prognosis.